Cempra, Inc. (CEMP) to Release Quarterly Earnings on Monday
Cempra, Inc. (NASDAQ:CEMP) will be issuing its quarterly earnings data before the market opens on Monday, July 31st. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.
Cempra (NASDAQ:CEMP) last issued its quarterly earnings results on Friday, April 28th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.16. The firm had revenue of $4.87 million during the quarter, compared to analyst estimates of $3.55 million. Cempra had a negative return on equity of 56.60% and a negative net margin of 551.45%. During the same period last year, the company posted ($0.61) EPS. On average, analysts expect Cempra to post $-1.06 EPS for the current fiscal year and $-0.86 EPS for the next fiscal year.
Cempra, Inc. (CEMP) opened at 4.35 on Monday. The firm’s 50-day moving average price is $4.20 and its 200-day moving average price is $3.77. The company’s market capitalization is $228.39 million. Cempra, Inc. has a 52 week low of $2.55 and a 52 week high of $26.95.
Several research firms recently weighed in on CEMP. ValuEngine cut shares of Cempra from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Jefferies Group LLC reaffirmed a “hold” rating and set a $3.00 target price on shares of Cempra in a report on Thursday, May 25th. Zacks Investment Research lowered shares of Cempra from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. Robert W. Baird reaffirmed an “underperform” rating on shares of Cempra in a report on Tuesday, March 28th. Finally, Gabelli lowered shares of Cempra from a “hold” rating to a “sell” rating in a report on Wednesday, March 29th. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $11.34.
ILLEGAL ACTIVITY WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/07/24/cempra-inc-cemp-to-release-quarterly-earnings-on-monday.html.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.